Given that exosomes express different forms of EGFR, the molecular target of Cetuximab [55 - 57], extracellular binding between Cetuximab and exosomal EGFR could reduce antibody binding to CRC cancer cells, partially neutralizing the effects of antibody-based therapeutics. This evidence concerns the gene EGFR and cancer.